What Is SDGR Stock? Schrödinger Overview

SDGR is the Nasdaq ticker symbol for Schrödinger, Inc. (Nasdaq: SDGR), a New York-based company founded in 1990 that builds physics-based computational chemistry software for pharmaceutical companies and runs its own internal drug discovery programs. The company sits at an unusual intersection: part software business, part biotech, and fully difficult to categorize by standard screener definitions.

Schrödinger is best known for its physics-based software platform, which pharmaceutical companies use to predict how potential drug molecules will bind to disease-causing proteins, accelerating drug discovery without the cost of endless physical experiments. Gates Ventures, the personal investment vehicle of Bill Gates, was a notable investor in Schrödinger prior to and following its February 2020 IPO.

Editorial Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice, a securities recommendation, or an offer to buy or sell any financial instrument. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Investing in stocks involves risk, including the possible loss of principal.

Schrödinger, Inc.: Company at a Glance

Gates Ventures, Bill Gates's investment firm, has been an investor in Schrödinger since before the company's IPO, a fact that contributed to Schrödinger's public profile ahead of its 2020 listing.

Some financial data platforms classify SDGR under Technology or Software due to its SaaS revenue model. This reflects the company's hybrid business structure, which the next section addresses directly.

What Does Schrödinger, Inc. Actually Do?

Schrödinger, Inc. does two things: it licenses computational chemistry software to pharmaceutical companies, and it uses that same software to discover drugs through its own internal programs and paid collaboration agreements with pharma partners.

The field Schrödinger operates in is called computational drug discovery: the use of computer simulations to predict how potential drug molecules will interact with proteins in the human body, reducing the need for expensive and time-consuming physical lab experiments. Think of it as running a virtual crash test on a drug molecule before manufacturing a single pill. The simulations fail fast and cheaply so that physical experiments can focus on the most promising candidates.

The market for these tools exists because drug discovery is expensive. Bringing a single drug from initial research to market approval costs more than $1 billion on average. Computational tools reduce the number of failed experiments along the way, which is why large pharmaceutical companies pay for Schrödinger's platform.

Schrödinger's physics-based approach is distinct from data-driven machine learning methods used by some competitors. Rather than learning patterns from historical drug data, Schrödinger's tools derive predictions from the fundamental laws of molecular physics. That distinction matters for how investors evaluate the company's competitive position.

Is SDGR a biotech stock or a software stock? SDGR is both. Schrödinger operates as a software company (licensing computational chemistry tools to pharmaceutical clients) and as a drug discovery company (developing its own pipeline and earning milestone payments from pharma collaborations). This hybrid model is why it appears in different sector classifications depending on the data source.

How Does Schrödinger Make Money? The Two-Part Business Model

Schrödinger generates revenue from two distinct business segments: software licensing and drug discovery collaborations. A useful way to think about it: the company builds high-precision carpentry tools, licenses them to professional builders, and also builds its own furniture using those same tools, occasionally selling the designs to major manufacturers for significant fees.

Because of this dual model, SDGR does not fit neatly into either the software or biotech category. Different screeners classify it differently, and some traditional valuation metrics do not apply cleanly.

Segment 1: Software Licensing

Schrödinger licenses its computational chemistry platform, including Maestro, FEP+, and the Glide docking module, to pharmaceutical and biotech companies on annual subscription or term-license terms. Customers include Pfizer and Bristol-Myers Squibb, as well as AstraZeneca, Takeda, and hundreds of smaller biotech firms. This segment functions as the picks-and-shovels layer of the drug discovery industry: relatively predictable, recurring revenue that does not depend on any single drug candidate succeeding.

Software licensing revenue is reported separately from drug discovery revenue in Schrödinger's SEC filings. When reading quarterly results, these two lines behave differently, and conflating them creates a distorted picture of the business.

Segment 2: Drug Discovery Collaborations and Internal Pipeline

Schrödinger also uses its own platform to discover drugs. This happens in two ways: through internal programs where Schrödinger owns the drug candidates outright, and through paid collaboration agreements with pharmaceutical partners.

Revenue from this segment includes upfront payments (paid when a deal is signed), research funding (annual payments during active collaboration), milestone payments (a payment triggered when a drug candidate reaches a defined development stage, such as entering clinical trials), and potential downstream royalties on any approved drugs.

This revenue is lumpy: non-recurring amounts that arrive in irregular patterns rather than predictable periodic payments. A single milestone triggered by a clinical trial result can generate tens of millions in one quarter, followed by minimal collaboration revenue the next. That is why SDGR's quarterly revenue can look erratic and why annual trends are more informative than quarter-to-quarter comparisons.

Does Schrödinger have its own drug pipeline? Yes. Beyond licensing software, Schrödinger operates its own internal drug discovery programs. Some of these candidates have advanced into clinical trials. This internal pipeline represents a second potential value driver beyond software licensing revenue, but also introduces biotech-style pipeline risk.

Schrödinger's Software Platform: FEP+, Maestro, and Glide Explained

Schrödinger's software platform is the foundation of its business: the tools that pharmaceutical scientists use to design drug candidates faster and with fewer failed experiments. Three products define the platform, each representing a distinct layer of the drug discovery workflow.

What Is FEP+ and Why Does It Matter?

FEP+ (Free Energy Perturbation Plus) is Schrödinger's flagship computational method and its primary competitive moat. Think of FEP+ as a high-precision digital lock-and-key tester. It calculates, with physics-based accuracy, exactly how tightly a potential drug molecule (the key) binds to a disease-causing protein (the lock). The tighter the predicted binding affinity (the strength of the attraction between a drug molecule and its target protein), the more likely the drug candidate is to be effective.

FEP+ (Free Energy Perturbation Plus) Schrödinger's physics-based computational method for predicting how strongly a drug molecule binds to its biological target. Higher binding accuracy means fewer failed drug candidates and lower drug development costs for pharmaceutical companies.

The underlying free energy perturbation method has existed in academic computational chemistry for decades. Schrödinger's contribution was making it computationally practical and commercially scalable. FEP+ is not an AI system: it derives predictions from the fundamental laws of molecular physics, not from pattern recognition in historical data. This distinction separates Schrödinger from machine learning-first competitors, and it matters for certain drug target classes where historical training data is limited.

Pfizer and AstraZeneca use FEP+ in their drug discovery programs. Bristol-Myers Squibb is also an adopter. Schrödinger claims FEP+ achieves higher accuracy than purely ML-based approaches for certain target classes, a claim that underpins the company's premium pricing.

Maestro is Schrödinger's primary software interface: the integrated workbench that bundles FEP+, Glide, and other specialized modules into a single environment. Think of it as the Adobe Creative Suite of computational chemistry. Just as Creative Suite combines Photoshop and Illustrator into one platform, Maestro makes all of Schrödinger's tools accessible from one interface. Its widespread use in both pharmaceutical companies and graduate school research programs creates brand stickiness over time. Scientists who trained on Maestro during their PhD programs often bring that familiarity into industry roles.

Schrödinger's Glide docking module predicts how a drug candidate geometrically fits into a protein's binding site, a process called molecular docking. Glide is among the most widely adopted docking tools in the pharmaceutical industry. Research teams that have built workflows around it face significant switching costs, which creates customer lock-in and supports Schrödinger's recurring software revenue.

Beyond FEP+ and Glide, Schrödinger's suite includes specialized modules such as WaterMap, which models how water molecules behave within a protein's binding site to help chemists refine drug candidates.

The most concrete real-world validation of Schrödinger's FEP+ platform came in January 2023, when Nimbus Therapeutics, a private biotech company that built its TYK2 inhibitor drug program using Schrödinger's platform, sold that program to Takeda Pharmaceutical for approximately $4 billion upfront. To be precise: Takeda paid approximately $4 billion for Nimbus's TYK2 inhibitor program specifically, not for Nimbus Therapeutics as a whole company. The deal demonstrated that physics-based computational drug discovery can produce drug candidates valuable enough for billion-dollar acquisitions. Schrödinger held an equity stake in Nimbus and participated in the economic upside of the transaction.

SDGR Stock History: From IPO to Today

Schrödinger went public on February 6, 2020, listing on the Nasdaq Global Select Market under the ticker SDGR at an IPO price of $17 per share.

Schrödinger was founded in 1990 by Richard Friesner, a Columbia University computational chemistry professor whose academic research formed the scientific foundation for the company's physics-based simulation methods. The company spent nearly three decades as a private company before the 2020 IPO.

SDGR surged through 2020 as investor enthusiasm for computational biology accelerated. The stock reached approximately $115 per share in early 2021. The sharp decline from that peak was driven primarily by macro factors: rising interest rates through 2021 and 2022 compressed valuations across pre-profitability growth stocks broadly, not just SDGR. Investors who purchased SDGR near its 2021 peak experienced significant losses, a pattern common across the pre-profitability biotech and computational biology category during the 2022 rate-hiking cycle.

SDGR-specific factors also contributed to the volatility: the lumpy nature of drug discovery collaboration revenue makes quarterly results hard to predict, and investor uncertainty around the path to profitability has weighed on the stock's multiple.

For the current SDGR stock price, check Nasdaq.com or your brokerage platform using the ticker SDGR.

SDGR Financial Overview

As of its most recent annual filing, Schrödinger is not yet profitable on a GAAP basis. The company continues to invest heavily in platform development and internal drug discovery programs, which means operating expenses currently exceed total revenues. [Writer: insert most recent fiscal year net loss figure with year attribution from Form 10-K at time of publication.]

All figures above must be sourced from Schrödinger's most recent Form 10-K, available at SEC EDGAR. For the current market capitalization, check Nasdaq.com or a financial data provider using the ticker SDGR.

Because Schrödinger is not yet profitable, investors typically assess the stock using revenue-based metrics such as the Price-to-Sales (P/S) ratio, which compares the company's market capitalization to its annual revenue. This differs from the price-to-earnings (P/E) ratio used for profitable companies: since Schrödinger has no positive earnings to measure, the P/E metric does not apply. P/S multiples for computational biology and SaaS companies vary based on growth rate and competitive position.

Drug discovery collaboration revenue adds complexity to the financial picture because it is lumpy. A quarter that includes a large milestone payment can show revenue well above the software licensing run-rate, while the following quarter may show a sharp drop. Annual revenue trends are more meaningful for SDGR than quarterly comparisons.

Management has discussed a path toward non-GAAP profitability through continued software revenue growth. For the most current guidance, consult Schrödinger's most recent earnings call transcript at ir.schrodinger.com.

How Does SDGR Compare to Other Computational Drug Discovery Stocks?

Schrödinger is not the only public company applying computational technology to drug discovery, but it approaches the problem differently than its closest peers.

Physics-based approaches like Schrödinger's FEP+ derive predictions from the fundamental laws of molecular physics, simulating molecular interactions at the atomic level. Machine learning approaches, such as those used by Recursion Pharmaceuticals (Nasdaq: RXRX), learn patterns from large datasets of biological images or experimental results. The two approaches are not mutually exclusive, but they represent different bets about where the most predictive signal in drug discovery lies. Schrödinger bets on physics accuracy and scientific precision; Recursion bets on data volume and pattern recognition.

Relay Therapeutics (RLAY) is simultaneously a Schrödinger software customer and a pipeline competitor in certain drug discovery areas, illustrating how SDGR's customer base and competitive landscape can overlap. Schrödinger also competes globally with AI-driven drug discovery companies including Insilico Medicine and BenevolentAI, though neither trades on U.S. exchanges.

For investors comparing these companies, the question is not which approach is better but which company's specific implementation, business model, and development stage best fits their investment thesis and risk profile.

Key Risks and Investment Considerations for SDGR

SDGR carries specific risks that investors should understand before evaluating it as a potential portfolio addition. The following covers the key factors analysts and investors typically weigh. This is not a buy or sell recommendation.

Key Risks to Understand

• Pre-profitability status. Schrödinger currently operates at a net GAAP loss. The path to GAAP profitability has not yet been achieved, which means the company funds operations from its cash reserves and any capital market activity. Companies at this stage face execution risk if revenue growth slows while expenses remain elevated.

• Lumpy collaboration revenue. Drug discovery milestone payments are non-recurring and arrive sporadically. A large milestone in one quarter may not repeat the next, making quarterly revenue comparisons less meaningful than annual trends. Investors who react to individual quarterly misses without understanding this dynamic may misread the business.

• Pipeline risk. Schrödinger's internal drug candidates may fail in clinical trials. There is no guarantee that pipeline programs will reach regulatory approval or generate the milestone payments that investors may be pricing into the stock.

• Customer concentration. A significant portion of software licensing revenue may be concentrated among a small number of large pharmaceutical customers. If key customers reduce spending or build competing internal capabilities, software revenue could decline.

• Competition from in-house pharma AI. Large pharmaceutical companies are building internal computational capabilities. Increased in-house capacity could reduce demand for third-party platforms like Schrödinger's over time, a risk that is hard to quantify but real.

• Valuation sensitivity to interest rates. As a high-Price-to-Sales (P/S), pre-profitability stock, SDGR's valuation is sensitive to changes in interest rates and broader shifts in market risk appetite. When rates rise, growth-stock multiples compress. SDGR's price history from 2021 to 2022 illustrates this dynamic.

Who Is SDGR Suited For?

SDGR may suit investors who:

• Take a long-term investment horizon (5+ years)
• Carry high risk tolerance for pre-profitability companies
• Hold a thesis-based conviction that computational drug discovery will become a core part of pharmaceutical R&D
• Are comfortable with revenue lumpiness and valuation volatility tied to pipeline news

SDGR is likely not suited for:

• Income investors (Schrödinger pays no dividend)
• Value investors seeking low P/S multiples or near-term earnings
• Risk-averse investors who require near-term profitability as a condition for investment

If you are a long-term investor comfortable with pre-profitability risk and thesis-driven volatility, SDGR may be worth adding to your research watchlist before committing to deeper due diligence.

SDGR in 2025: Key Factors to Watch

The factors analysts and investors typically track for SDGR include: progress in the software licensing segment's annual revenue growth rate, new drug discovery collaboration announcements or milestone triggers, pipeline candidate advancement through clinical stages, and management's updated guidance on the timeline to non-GAAP profitability. For the most current pipeline status and financial guidance, consult Schrödinger's most recent earnings call transcript and investor presentation at ir.schrodinger.com.

[Editor note: Update this sub-section at each quarterly earnings release with current pipeline status, guidance updates, and key upcoming catalysts.]

SDGR is a thesis-driven investment. Its value is tied to the long-term belief that physics-based computational drug discovery will become a fundamental part of pharmaceutical R&D. Investors who share that thesis and accept pre-profitability risk and revenue lumpiness may find SDGR worth researching further. Those who prioritize near-term profitability or low volatility may find other opportunities more suitable.

Frequently Asked Questions About SDGR Stock

What is SDGR stock?

SDGR is the Nasdaq ticker symbol for Schrödinger, Inc., a computational chemistry software company that also operates an internal drug discovery pipeline. The company provides physics-based simulation software to pharmaceutical companies and conducts its own drug discovery programs alongside its software licensing business.

Is SDGR a biotech stock or a software stock?

SDGR is both. Schrödinger operates as a software company (licensing computational chemistry tools to pharmaceutical clients) and as a drug discovery company (developing its own pipeline and earning milestone payments from pharma collaborations). This hybrid model is why SDGR appears in different sector classifications depending on the data source. Neither label alone captures what the company does.

When did Schrödinger go public?

Schrödinger went public on February 6, 2020, listing on the Nasdaq Global Select Market under the ticker SDGR at an IPO price of $17 per share.

Who is the CEO of Schrödinger?

Schrödinger is led by Ramy Farid, Ph.D., a computational chemist who has served as President and CEO since 2010. His scientific background reflects the company's scientific-first culture.

Is Schrödinger profitable?

As of its most recent annual filing, Schrödinger is not yet profitable on a GAAP basis. The company invests heavily in software development and internal drug discovery R&D, resulting in an ongoing net loss. [Writer: insert most recent fiscal year net loss figure with year attribution from Form 10-K at time of publication.]

Who are Schrödinger's main customers?

Schrödinger's software customers include major pharmaceutical companies such as Pfizer and AstraZeneca. Bristol-Myers Squibb and Takeda are also customers, along with hundreds of smaller biotech firms worldwide.

Did Bill Gates invest in Schrödinger?

Yes. Gates Ventures, the personal investment vehicle of Bill Gates, was a notable investor in Schrödinger prior to and following its February 2020 IPO. This is a historical credibility marker and does not constitute a current endorsement of SDGR as an investment.

Does Schrödinger have its own drug pipeline?

Yes. Beyond licensing software, Schrödinger runs its own internal drug discovery programs. Some of these programs have advanced into clinical trials. This internal pipeline represents a second potential value driver and a second source of risk for SDGR investors.

What is FEP+ and why does it matter?

FEP+ (Free Energy Perturbation Plus) is Schrödinger's flagship computational method for predicting how strongly a potential drug molecule binds to its biological target. It uses physics-based simulation, not machine learning, to achieve high-accuracy binding predictions. FEP+ is considered Schrödinger's primary competitive moat and is used by major pharmaceutical companies including Pfizer and AstraZeneca.

What sector is SDGR classified in?

Schrödinger is classified under the Health Care sector within the Life Sciences Tools & Services industry group per the Global Industry Classification Standard (GICS). Some financial platforms classify it under Technology due to its SaaS software revenue, reflecting the hybrid nature of its business model.

The Bottom Line: What Is SDGR Stock?

Schrödinger, Inc. (Nasdaq: SDGR) is a New York-based company that licenses physics-based computational chemistry software to pharmaceutical firms and simultaneously runs its own internal drug discovery pipeline. This two-part structure gives SDGR characteristics of both a software company (recurring licensing revenue) and a biotech (pipeline optionality, milestone-driven revenue, and clinical trial risk).

The central thesis for owning SDGR is that physics-based computational drug discovery, anchored by its FEP+ platform, will become increasingly embedded in how pharmaceutical companies develop drugs. The Nimbus/Takeda $4 billion transaction for the TYK2 program in January 2023 is the strongest public proof point that the platform has produced commercially valuable outcomes.

The primary risks are pre-profitability status, lumpy drug discovery collaboration revenue, and the possibility that internal pipeline candidates do not advance to commercial milestones.

Investors who want to go deeper should consult Schrödinger's most recent Form 10-K and 10-Q filings at SEC EDGAR, the investor relations page at ir.schrodinger.com, and live stock data at Nasdaq.com using the ticker SDGR.

Editorial Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice, a securities recommendation, or an offer to buy or sell any financial instrument. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Investing in stocks involves risk, including the possible loss of principal.

Related Reading

• Aehr Test Systems stock price and live Nasdaq data
• Anthropic stock: current valuation and investment guide for 2025-2026
• AMC stock forecast: scenario framework for price expectations